---
category: news
title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
excerpt: "capabilities - Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations - First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole TOKYO,"
publishedDateTime: 2020-01-07T02:06:00Z
sourceUrl: https://www.benzinga.com/pressreleases/20/01/a15081848/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
ampUrl: https://amp.benzinga.com/amp/content/15081848
cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081848
type: article
quality: 14
heat: -1
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI
  - AI in Healthcare

related:
  - title: "Transgene starts trials of ‘digital’ cancer vaccine with NEC"
    excerpt: "The French biotech is partnering with artificial intelligence (AI) specialist NEC on the new programme – called TG4050 ... who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. It was also given a green light for a trial in head and neck cancer by the UK Medicines and Healthcare ..."
    publishedDateTime: 2020-01-07T13:20:00Z
    sourceUrl: https://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
    type: article
    provider:
      name: pharmaphorum.com
      domain: pharmaphorum.com
    quality: 24
    images:
      - url: https://www.bing.com/th?id=ON.3E4F78E119EB7DDFC3E305E5A0A6A184
        width: 700
        height: 467
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "\"As each patient's cancer is unique, we have developed a therapy that turns their solid tumor's genetic signature into a ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this ..."
    publishedDateTime: 2020-01-06T23:00:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/b15081336/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
    ampUrl: https://amp.benzinga.com/amp/content/15081336
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081336
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 14
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "\"As each patient's cancer is unique, we have developed a therapy that turns their solid tumor's genetic signature into a ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this ..."
    publishedDateTime: 2020-01-07T05:30:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/b15082025/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-individualized-ai-powered-cancer-vaccin
    ampUrl: https://amp.benzinga.com/amp/content/15082025
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15082025
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 6

secured: "rRHx7fOua144RaqxearS4kEIB+f8NPqH6420MBW7r+BrEynQ9Mxb5UkPCBUZLUiscQqr04QOt5nHG8n/6C3b+8YNelCaSTeFAiNig5rfO/3MkggVOC33maidNzm9HVwPYfFgp+lVw/beGpe4l83Db2Iu7FHG422oA50ZQhMzfZxP5NXCfkCpIDZpyZa1Ddkl9V7jl5SxmT5z+DjM6bBowCT7AguDYtoB2nJCf2B7NstEDCvCMuJHuoEHD4Spu2fEc8gH8st4QUOsCjmPtVzS8A==;zLCTwSCOK1g9vP8f5dFhoQ=="
---

